Last edition
News about "solid tumours"
Lupin to Present Phase 1 Data on LNP3693 (STING agonist) at ESMO Congress 2025
Lupin will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, scheduled to be held from October 17 to October 21, 2025.
Solid Tumours | 13/10/2025 | By Dineshwori | 111
CDSCO approves AstraZeneca's Trastuzumab Deruxtecan for More HER2-Positive Tumours
With this, Trastuzumab Deruxtecan becomes India’s first Antibody Drug Conjugate (ADC) approved for a tumour-agnostic indication.
Solid Tumours | 04/10/2025 | By Dineshwori | 176
Atavistik Bio Appoints Dr. Susan Pandya as Chief Medical Officer
As CMO, Dr. Susan Pandya will lead all clinical development strategy and execution for Atavistik Bio, including the ongoing Phase 1 clinical trial of its lead programme, ATV-1601.
Solid Tumours | 15/09/2025 | By Dineshwori | 104
SPARC Incorporates Wholly Owned Subsidiary Genokine Biotech in Vadodara
Sun Pharma Advanced Research Company Ltd. (SPARC) has incorporated a new wholly owned subsidiary, Genokine Biotech Ltd., with its registered office in Vadodara, Gujarat.
Solid Tumours | 09/07/2025 | By Dineshwori | 292
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy